1
P HENYLPROPANOLAMINE I NDUCED I NTRACEREBRAL H EMORRHAGE –T HE D IET P ILL B LEEDS A GAIN Wendy Chen, MD; Syed Omar Kazmi, MD; Bilal Butt, MD; Christos Lazaridis, MD, EDIC Division of Vascular Neurology and Neurocritical Care, Baylor College of Medicine, Houston, TX Patient was admitted to the Neurocritical Care Unit for her ICH score of 2. Lab work showed no evidence of coagulopathy or drug abuse. Patient became somnolent, repeat CTH showed hydrocephalus and worsening edema. Osmotherapy was initiated with no improvement. Four vessel digital subtraction angiography (Figure 3) was performed to further evaluate the etiology of her hemorrhage, results of which were unremarkable. Patient improved after a decompressive hemicraniectomy and was subsequently extubated. She was transferred to the inpatient rehabilitation unit and was eventually discharged with a wheelchair. H OSPITAL C OURSE In young patients with no known comorbidities, PPA use should be considered a primary etiology of ICH when no intracranial vessel abnormality can be detected. C ONCLUSION Intracerebral Hemorrhage (ICH) is a common pathology seen in the neurocritical care setting and is associated with significant morbidity and mortality. ICH accounts for 8-13% of all strokes with a 30-day mortality rate of 44%. Pheynylpropanolamine (PPA) is a alpha-adrenergic and beta-adrenergic receptor agonist as well as dopamine receptor D1 partial agonist that is found in appetite suppressants and decongestants. We report a case of ICH secondary to PPA use. I NTRODUCTION I MAGING Prior evidence had shown that PPA was associated with higher rates of ICH. In November 2000, the FDA formally recommended that PPA was not safe for OTC use and asked manufacturers to discontinue marketing of products containing PPA. Results of the Hemorrhagic Stroke Project led to the withdrawal of PPA from the US market in 2005. The drug was also withdrawn from the Canadian market in 2001. However, the drug is still available in Mexico, Europe and online markets and can be easily obtained as an over the counter medication. D ISCUSSION Figure 2 - CTA Vertically oriented vascular pedicle in the region of the posterior right lentiform nucleus, coursing through the hematoma, known as the spot sign. No malformations of aneurysm seen. Figure 1 - CTH Intraparenchymal hemorrhage in the right anterior striatocapsular region and insular cortex. Figure 3 - DSA Digital Subtraction Angiography revealed no aneurysms, vascular malformations, AV shunting, intracranial stenosis or evidence of vasospasm. Figure 4 - Repeat CTH Patient status post right decompressive craniectomy with residual hemorrhage. Figure 5 - MRI Diffusion restriction of right lentiform nucleus. Additional punctate foci of diffusion restriction are evident in the left cerebral hemisphere; a consequence of recent angiography. 1. Fallis RJ, Fisher M. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. Neurology 1985;35: 405-7. 2. Jick H, Aselton P, Hunter JR. Phenylpropanolamine and cerebral haemorrhage. Lancet 1984;1:1017. 3. Kase CS, Foster TE, Reed JE, Spatz EL, Girgis GN. Intracerebral hemorrhage and phenylpropanolamine use. Neurology 1987;37:399-404. 4. Kernan, WN et al. Phenylpropanolamine and the risk of hemorrhagic stroke. NEJM 2000; 343:1826-32. 5. Kikta DG, Devereaux MW, Chandar K. Intracranial hemorrhages due to phenylpropanolamine. Stroke 1985;16:510-2. 6. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990;89:195-208. 7. McDowell JR, LeBlanc HJ. Phenylpropanolamine and cerebral hemorrhage. West J Med 1985;142:688-91. 8. FDA letter to manufacturers of drug products containing Phenylpropanolamine (PPA) dated 11/03/2000. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm150774.htm. R EFERENCES Forty year old female with no prior medical history, who presented with acute onset headache and left sided hemiparesis and hemianesthesia. No history of trauma, was only taking a diet pill for weight reduction that she obtained from Mexico. Initial NIHSS of 16. Vital signs within normal range (BP - 128/84, P - 92, RR - 16, T - 96.5 F). C ASE P RESENTATION Download Poster

PHENYLPROPANOLAMINE INDUCED … INDUCED INTRACEREBRAL HEMORRHAGE – THE DIET PILL BLEEDS AGAIN. Wendy Chen, MD; Syed Omar Kazmi, MD; Bilal Butt, MD; Christos Lazaridis, MD, EDIC

  • Upload
    lythuan

  • View
    218

  • Download
    2

Embed Size (px)

Citation preview

Page 1: PHENYLPROPANOLAMINE INDUCED … INDUCED INTRACEREBRAL HEMORRHAGE – THE DIET PILL BLEEDS AGAIN. Wendy Chen, MD; Syed Omar Kazmi, MD; Bilal Butt, MD; Christos Lazaridis, MD, EDIC

PHENYLPROPANOLAMINE INDUCED INTRACEREBRALHEMORRHAGE – THE DIET PILL BLEEDS AGAIN

Wendy Chen, MD; Syed Omar Kazmi, MD; Bilal Butt, MD; Christos Lazaridis, MD, EDICDivision of Vascular Neurology and Neurocritical Care, Baylor College of Medicine, Houston, TX

Patient was admitted to the Neurocritical Care Unit for her ICH score of 2.

Lab work showed no evidence of coagulopathy or drug abuse.

Patient became somnolent, repeat CTH showed hydrocephalus and worsening edema. Osmotherapy was initiated with no improvement.

Four vessel digital subtraction angiography (Figure 3) was performed to further evaluate the etiology of her hemorrhage, results of which were unremarkable.

Patient improved after a decompressive hemicraniectomy and was subsequently extubated.

She was transferred to the inpatient rehabilitation unit and was eventually discharged with a wheelchair.

HOSPITAL COURSE

In young patients with no known comorbidities, PPA use should be considered a primary etiology of ICH when no intracranial vessel abnormality can be detected.

CONCLUSION

Intracerebral Hemorrhage (ICH) is a common pathology seen in the neurocritical care setting and is associated with significant morbidity and mortality.

ICH accounts for 8-13% of all strokes with a 30-day mortality rate of 44%.

Pheynylpropanolamine (PPA) is a alpha-adrenergic and beta-adrenergic receptor agonist as well as dopamine receptor D1 partial agonist that is found in appetite suppressants and decongestants.

We report a case of ICH secondary to PPA use.

INTRODUCTION IMAGING

Prior evidence had shown that PPA was associated with higher rates of ICH.

In November 2000, the FDA formally recommended that PPA was not safe for OTC use and asked manufacturers to discontinue marketing of products containing PPA. Results of the Hemorrhagic Stroke Project led to the withdrawal of PPA from the US market in 2005. The drug was also withdrawn from the Canadian market in 2001.

However, the drug is still available in Mexico, Europe and online markets and can be easily obtained as an over the counter medication.

DISCUSSION

Figure 2 - CTAVertically oriented vascular pedicle in the region of the posterior right lentiform nucleus, coursing through the hematoma, known as the spot sign. No malformations of aneurysm seen.

Figure 1 - CTH Intraparenchymalhemorrhage in the right anterior striatocapsularregion and insular cortex.

Figure 3 - DSADigital Subtraction Angiography revealed no aneurysms, vascular malformations, AV shunting, intracranial stenosis or evidence of vasospasm.

Figure 4 - Repeat CTHPatient status post right decompressive craniectomy with residual hemorrhage.

Figure 5 - MRIDiffusion restriction of right lentiform nucleus. Additional punctate foci of diffusion restriction are evident in the left cerebral hemisphere; a consequence of recent angiography.

1. Fallis RJ, Fisher M. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. Neurology 1985;35:405-7.

2. Jick H, Aselton P, Hunter JR. Phenylpropanolamine and cerebral haemorrhage. Lancet 1984;1:1017.

3. Kase CS, Foster TE, Reed JE, Spatz EL, Girgis GN. Intracerebral hemorrhage and phenylpropanolamine use. Neurology 1987;37:399-404.

4. Kernan, WN et al. Phenylpropanolamine and the risk of hemorrhagic stroke. NEJM 2000; 343:1826-32.

5. Kikta DG, Devereaux MW, Chandar K. Intracranial hemorrhages due to phenylpropanolamine. Stroke 1985;16:510-2.

6. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med 1990;89:195-208.

7. McDowell JR, LeBlanc HJ. Phenylpropanolamine and cerebral hemorrhage. West J Med 1985;142:688-91.

8. FDA letter to manufacturers of drug products containing Phenylpropanolamine (PPA) dated 11/03/2000. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm150774.htm.

REFERENCES

Forty year old female with no prior medical history, who presented with acute onset headache and left sided hemiparesis and hemianesthesia.

No history of trauma, was only taking a diet pill for weight reduction that she obtained from Mexico.

Initial NIHSS of 16.

Vital signs within normal range (BP - 128/84, P - 92, RR - 16, T - 96.5 F).

CASE PRESENTATION

DownloadPoster